Drug Safety Update
April 2014: There is an increased risk of tuberculosis, or reactivation of latent tuberculosis, during treatment with tumour necrosis factor alpha (TNF-alpha) inhibitors. TNF-alpha inhibitors are contraindicated in patients with active tuberculosis or other severe infections.
January 2015: Ustekinumab (Stelara): risk of exfoliative dermatitis
NICE Guidance (also see drug-specific NICE links below)
CG 152: Crohn's disease, October 2012
TA 633: Ustekinumab for treating moderately to severely active ulcerative colitis, June 2020